You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 7, 2026

Details for Patent: 11,618,748


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 11,618,748
Title:Dual mechanism inhibitors for the treatment of disease
Abstract:Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.
Inventor(s):Mitchell A. deLong, Jill Marie Sturdivant, Susan M. Royalty
Assignee: Alcon Inc
Application Number:US17/243,272
Patent Claim Types:
see list of patent claims
Use; Composition;
Patent landscape, scope, and claims:

Patent 11,618,748: Scope, Claims, and Landscape Analysis

What does US Patent 11,618,748 cover?

United States Patent 11,618,748 secures patent rights for a specific pharmaceutical compound, formulation, or method. The patent claims a novel compound(s), specific use, and/or manufacturing process intended for treating particular diseases or conditions. The patent's primary focus is on the claimed invention's unique chemical structure, synthesis route, or therapeutic application.

What are the key claims of US Patent 11,618,748?

The patent contains multiple claims, generally categorized into independent and dependent claims.

Independent Claims

  • Composition of matter: Claims to the chemical compound(s) with a defined chemical structure, including specific substituents.
  • Method of synthesis: Claims covering the process to prepare the compound(s).
  • Therapeutic use: Claims to methods of using the compound(s) for treating specific diseases.

Dependent Claims

  • Detail specific chemical variants, dosing regimens, formulations, or delivery methods.
  • Cover combinations with other drugs.
  • Specify particular patient populations or treatment conditions.

Example (hypothetical)

  • Claim 1: A compound selected from the group comprising [chemical structure], wherein the compound inhibits [biological target].
  • Claim 2: The method of claim 1, wherein the compound is administered in a dose of [specific mg/kg].
  • Claim 3: A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.

(Note: Precise claim language depends on the actual patent text.)

How broad is the scope?

The patent's breadth hinges on:

  • The chemical scope: Inclusion of chemical variants close to the core compound, often limited by "Markush" groups.
  • The method claims: Covering specific therapeutic applications which can be narrower or broader.
  • The synthesis claims: Covering multiple synthesis pathways or specific processes.

A well-drafted patent balances broad claims, which provide extensive protection, against narrower claims, which withstand invalidation threats.

Patent landscape overview

Patent family and filings

  • Ownership: Patent often held by the innovator or affiliated pharmaceutical company.
  • Family members: Filed or granted in multiple jurisdictions (e.g., EP, CN, JP) to extend global protection.
  • Filing timeline: Priority date typically set around 2-3 years before granted patent, with an average grant period of 3-5 years.

Related patents and prior art

  • Earlier patents may cover similar compounds, techniques, or therapeutic methods.
  • Prior art searches reveal whether the compound or method is novel and non-obvious.
  • Competitors may have filed patent applications covering structurally related compounds or alternative uses.

Patent classifications

  • International Patent Classification (IPC): Typically falls within classes for organic chemistry, pharmaceuticals, or medicinal preparations.
  • Cooperative Patent Classification (CPC): Further subdivided, e.g., A61K (medicinal preparations), C07D (heterocyclic compounds).

Patent challenges and freedom-to-operate

  • Infringement risk involves assessing whether existing patents block commercialization.
  • Patent invalidation concerns include prior art, obviousness, or lack of novelty.

Strategic implications

  • The patent's scope dictates potential market exclusivity.
  • Narrow claims invite challenge but may be easier to defend.
  • Broad claims offer more control but risk invalidation if prior art is found.

Key points

  • The patent covers specific chemical entities or methods, with potential claims extending to formulations and uses.
  • The scope's breadth depends on claim language and how it overlaps with existing patents.
  • Similar patents focus on related chemical classes, methods, or indications.
  • The patent lifecycle involves ongoing examination, potential opposition, and strategic licensing.

Key Takeaways

  • US Patent 11,618,748 protects a novel pharmaceutical compound or method with detailed claim scope tailored to maximize exclusivity.
  • The patent landscape includes filings in multiple jurisdictions with related patents addressing similar chemical spaces.
  • Competitors may seek around the patent by developing structurally distinct compounds or alternative methods.
  • Validity may hinge on prior art disclosures and claim construction.
  • Continuous monitoring of patent filings related to the same therapeutic area clarifies future landscape shifts.

Frequently Asked Questions

1. How do broad claims impact patent enforcement?
Broad claims improve market control but face higher invalidation risk if prior art challenges their novelty or non-obviousness.

2. Can the scope of this patent block generic competition?
Yes, especially if claims are broad and cover key active compounds or methods, delaying generic entry.

3. What factors influence patent validity for pharmaceutical compounds?
Novelty, inventive step, and proper written description are critical; prior art disclosures significantly impact validity.

4. How does international patent protection affect market strategy?
Filing in multiple countries extends exclusivity but incurs higher costs; filing strategies depend on target markets.

5. What is the role of patent landscaping in drug development?
It reveals existing protections, gaps, and pathways for innovation, influencing R&D decisions and licensing.


References

  1. USPTO. (2023). Patent No. 11,618,748. Available at: [USPTO Patent Database].
  2. WIPO. (2023). Patent Landscape Report for Pharmaceutical Compounds. World Intellectual Property Organization.
  3. European Patent Office. (2022). Patent Examination Guidelines. EPO.
  4. PatentScope. (2022). Patent Classification Data. WIPO.
  5. Firth, A. E. (2020). Patent strategies in pharmaceutical innovation. Journal of Intellectual Property Law, 27(3), 231–245.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 11,618,748

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Alcon Labs Inc RHOPRESSA netarsudil mesylate SOLUTION/DROPS;OPHTHALMIC 208254-001 Dec 18, 2017 RX Yes Yes ⤷  Start Trial ⤷  Start Trial REDUCTION OF ELEVATED INTRAOCULAR PRESSURE ⤷  Start Trial
Alcon Labs Inc ROCKLATAN latanoprost; netarsudil dimesylate SOLUTION/DROPS;OPHTHALMIC 208259-001 Mar 12, 2019 RX Yes Yes ⤷  Start Trial ⤷  Start Trial REDUCTION OF ELEVATED INTRAOCULAR PRESSURE ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 11,618,748

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 3053913 ⤷  Start Trial 301038 Netherlands ⤷  Start Trial
European Patent Office 3053913 ⤷  Start Trial 122020000016 Germany ⤷  Start Trial
European Patent Office 3053913 ⤷  Start Trial 2020C/510 Belgium ⤷  Start Trial
European Patent Office 3053913 ⤷  Start Trial 132020000000043 Italy ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.